Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTABARBITAL SODIUM vs ALLZITAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.
Preoperative sedation,Daytime sedation,Insomnia (short-term treatment),Status epilepticus (adjunct),Withdrawal syndrome (off-label)
Sedation,Short-term treatment of insomnia,Management of seizure disorders (generalized tonic-clonic and partial seizures),Preoperative anxiety
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 8-12 hours in renal impairment.
Primarily hepatic via CYP2C9, CYP2C19, and CYP3A4; conjugated with glucuronic acid; excreted renally.
Primarily hepatic via CYP2C9, CYP2C19, and glucuronidation; metabolized to inactive metabolites (e.g., p-hydroxyphenobarbital) that are excreted renally.
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Renal: 70% as unchanged drug; biliary/fecal: 20% as metabolites; 10% other.
25-35%, primarily to albumin
92% bound to albumin and alpha-1-acid glycoprotein.
0.5-0.8 L/kg; distributes widely into tissues, crosses blood-brain barrier
2.5-3.5 L/kg; large Vd indicates extensive tissue distribution.
Oral: 80-100% (rapid absorption); IM: complete
Oral: 85-90% due to first-pass metabolism; intravenous: 100%.
Contraindicated in severe renal impairment (e GFR <30 m L/min). For e GFR 30-50 m L/min: reduce dose by 25% and monitor for CNS depression. e GFR >50 m L/min: no adjustment.
GFR 30-50 m L/min: 50% dose reduction; GFR <30 m L/min: avoid use.
Contraindicated in Child-Pugh Class C. Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75% or use alternative. Avoid in severe hepatic impairment.
Child-Pugh Class B: 50% dose reduction; Child-Pugh Class C: avoid use.
Not recommended for children <6 years. For children 6-12 years: sedative 5-15 mg orally 3-4 times daily; hypnotic not typically used. For adolescents >12 years: adult dosing with caution. Maximum single dose: 30 mg. Weight-based: 2-3 mg/kg/day divided every 6-8 hours, not to exceed 100 mg/day.
0.1-0.2 mg/kg orally every 4-6 hours as needed; maximum single dose 5 mg; not to exceed 20 mg per day.
Start with lowest effective dose (e.g., 15 mg orally for sedation). Maximum dose: 50 mg per dose. Caution due to increased sensitivity, risk of falls, and cognitive impairment. Avoid hypnotic use. Consider non-barbiturate alternatives.
Initiate at 2.5 mg orally every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Barbiturates are habit-forming. Tolerance, psychological and physical dependence may occur. Withdrawal symptoms include delirium, convulsions, and death. Abrupt cessation after prolonged use is not recommended.
Risk of respiratory depression, particularly with rapid IV administration or excessive doses; co-administration with CNS depressants (e.g., opioids, alcohol) may exacerbate this effect. Use in pregnancy may cause fetal harm (teratogenic effects).
Respiratory depression risk; use caution in hepatic impairment, renal impairment, elderly, or debilitated patients; avoid abrupt discontinuation; may cause paradoxical excitement; monitor for hypersensitivity reactions.
Respiratory depression, CNS depression, dependence and withdrawal (taper gradually), paradoxical excitation (especially in elderly), use in hepatic or renal impairment, drug interactions with warfarin, oral contraceptives, and corticosteroids.
Hypersensitivity to barbiturates, porphyria, severe respiratory disease, severe hepatic impairment, history of addiction to sedative-hypnotics.
Hypersensitivity to barbiturates, severe respiratory insufficiency, history of porphyria, severe hepatic impairment, pregnancy (especially first trimester).
Avoid grapefruit juice as it may alter metabolism. Limit or avoid alcohol; concurrent use increases CNS depression risk. Take with food if GI upset occurs; avoid high-fat meals as they may slow absorption.
Avoid excessive alcohol consumption; may increase hepatotoxicity. No significant food interactions. Take with or without food; food may reduce GI upset.
First trimester: Increased risk of major malformations, particularly oral clefts (odds ratio 2.0-3.0). Second trimester: Risk of neural tube defects and cardiac anomalies. Third trimester: Neonatal withdrawal syndrome, respiratory depression, and hemorrhagic disease due to vitamin K deficiency. FDA Category D.
Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbiturate use may lead to neonatal withdrawal and coagulation defects due to vitamin K deficiency; use only if benefit outweighs risk.
Excreted in breast milk; M/P ratio estimated 0.3-0.5. Risk of infant sedation, poor feeding, and withdrawal. Contraindicated in breastfeeding unless essential. Monitor for drowsiness, weight gain, and developmental milestones.
Butalbital and acetaminophen are excreted into breast milk in low amounts. Caffeine also enters milk. M/P ratio not established for butalbital. Use caution; monitor infant for sedation, poor feeding. American Academy of Pediatrics considers butalbital compatible with breastfeeding but avoid prolonged use.
Increased clearance (up to 50% higher) in pregnancy, especially third trimester. Dose may need to be increased by 30-50% to maintain therapeutic effect. Monitor serum levels and adjust to minimum effective dose.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes (increased volume of distribution, hepatic metabolism) may reduce butalbital levels; clinical efficacy not well studied. Use lowest effective dose shortest duration. Acetaminophen doses remain standard (<4 g/day). Avoid caffeine >300 mg/day.
Barbiturate with rapid onset used for preoperative sedation and seizure control. Respiratory and CNS depression risk is dose-dependent; avoid in porphyria. Tolerance develops with prolonged use; withdrawal can be life-threatening. Use as second-line for status epilepticus after benzodiazepines. Highly protein-bound; monitor for interactions with warfarin and oral contraceptives.
ALLZITAL is a combination analgesic containing acetaminophen and tramadol. Monitor for serotonin syndrome when used with other serotonergic drugs. Avoid in patients with severe hepatic impairment or acute alcohol intoxication. Maximum daily acetaminophen dose is 4000 mg; reduce in hepatic risk. Tramadol may lower seizure threshold; use cautiously in epilepsy. Not recommended in breastfeeding due to tramadol excretion. Adjust dose in renal impairment (Cr Cl <30 m L/min: extended interval). Discontinue gradually to avoid withdrawal.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol and other CNS depressants (e.g., opioids, benzodiazepines).,Do not drive or operate machinery until you know how this drug affects you.,Do not stop suddenly; abrupt discontinuation can cause withdrawal seizures.,Inform your doctor if you have a history of porphyria, liver disease, or depression.,Use effective contraception; this drug may reduce hormonal contraceptive efficacy.
Do not exceed 8 tablets per day due to acetaminophen liver risk.,Avoid alcohol and other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until effect known.,Report signs of serotonin syndrome (agitation, hallucinations, rapid heart rate).,Do not stop suddenly; taper to prevent withdrawal symptoms.,Store at room temperature away from moisture.,Use only as prescribed; risk of dependence with tramadol.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTABARBITAL SODIUM vs ALLZITAL, answered by our medical review team.
BUTABARBITAL SODIUM is a Barbiturate that works by Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.. ALLZITAL is a Barbiturate Analgesic Combination that works by Allzital contains phenobarbital, a barbiturate that enhances GABA-A receptor activity by increasing the duration of chloride ion channel opening, leading to neuronal hyperpolarization and inhibition of neurotransmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTABARBITAL SODIUM and ALLZITAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTABARBITAL SODIUM is: Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.. The standard adult dose of ALLZITAL is: 5-10 mg orally every 4-6 hours as needed for pain; not to exceed 40 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUTABARBITAL SODIUM and ALLZITAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUTABARBITAL SODIUM is classified as Category C. First trimester: Increased risk of major malformations, particularly oral clefts (odds ratio 2.0-3.0). Second trimester: Risk of neural tube defects and cardiac anomalies. Third tr. ALLZITAL is classified as Category C. Allzital (butalbital/acetaminophen/caffeine) is category C. First trimester: risk of neural tube defects increased with barbiturate exposure; avoid. Second/third trimester: barbitu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.